Chakradhar Thupili, MD

Education

Medical School

Kurnool Medical College, Kurnool, India, 1994

Internship

Government General Hospital, Kurnool, India, 1994

Residency

Radiodiagnosis, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2002

Fellowship

Abdominal Imaging and Nonvascular Intervention, The Ottawa Hospital, Ottawa, Canada, 2008

Fellowship

Abdominal Imaging, Cleveland Clinic, Cleveland, Ohio, 2009

Fellowship

Pediatric Radiology, The Ottawa Hospital, Ottawa, Canada, 2014

Areas of Interest

Research Interests

**Faculty profiles will only highlight current information (the last three years). Please request the faculty’s CV for more information.

Research and Grants
Past Research Studies:

1. LIGHT protocol – PI: Lucci, Co-Investigator C. Thupili. – Astra Zeneca
   Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy Start Date 11/06/17
2. ATHENA protocol – Clovis Oncology – PI: Lucci, Co-Investigator C. Thupili.
   A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy – Start Date – 06/08/18
3. LEE protocol – PI: Lucci, Co-Investigator C. Thupili. – Novartis-GOG A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum – Start Date – 01/02/19
4. OVAL protocol – PI: Lucci Co-Investigator C. Thupili., – VBL Therapeutics – GOG“The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer”: Start Date – 01/08/19
5. The Revita™ US Pilot Study – Fractyl Laboratories– PI: Gutierrez (with Dr. Tammisetti), Co-Investigator C. Thupili. Randomized, Double-Blind, Sham-Controlled, Prospective, Multi-Center Pilot Study to Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing Using the Revita™ System in the Treatment of Type 2 Diabetes – 5/2019

Publications

Honors and Awards

**Faculty profiles will only highlight current information (the last three years). Please see the faculty’s CV for more information.

Certificates of proficiency or merit” RSNA 2019 for Prostate MRI and
MR-Directed Biopsy (MRDB) Service: A Template for Quality Assurance Program and Peer-Collaborative Learning